Business
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health
PURCHASE, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in Vision and Ophthalmology (ARVO) showing the potential for zervimesine (CT1812) to protect retinal pigment epithelial (RPE) cells from damage in dry age-related macular degeneration (dry AMD). "Dry AMD is driven by a number of factors that contribute to
About this update from Cognition Therapeutics, Inc.
[{"type":"image","alt":"Cognition Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Cognition Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":250,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/cc90d0cfc1ad93cdee05813266446f22"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3G97CJjBroOGRUYevL.t.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cc90d0cfc1ad93cdee05813266446f22","width":250,"height":70}},"lazy":false},{"type":"text","content":"PURCHASE, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in Vision and Ophthalmology (ARVO) showing the potential for zervimesine (CT1812) to protect retinal pigment epithelial (RPE) cells from damage in dry age-related macular degeneration (dry AMD).","length":444,"tagName":"p"},{"type":"text","content":""Dry AMD is driven by a number of factors that contribute to the death of retinal cells, leading to irreversible vision loss," stated Mary Hamby, PhD, vice president of research. "Preclinical research presented at ARVO supports our understanding of zervimesine’s potential for supporting retinal cell health and function."","length":342,"tagName":"p"},{"type":"text","content":"Zervimesine is an oral drug candidate that has been shown to reach therapeutic concentrations in the eye and was investigated in the Phase 2 MAGNIFY clinical trial (NCT05893537). It binds to a receptor (TMEM97, also called the sigma-2 receptor), which is found on cells in the retina and brain. A poster presented by research scientist, Britney Lizama, PhD, shows that this receptor regulates the ability of retinal cells to take in low-density lipoprotein (LDL), a major fuel source for cells. The process that cells use to take in lipids is damaged in dry AMD, weakening the retinal cells and contributing to their mortality.","length":627,"tagName":"p"},{"type":"text","content":"A second poster presented by Drs. Hamby and Lizama, shows zervimesine may protect retinal cells from the onslaught of oxidized lipids. In dry AMD, oxidized lipids build up in the retina. Together with other waste products, these lipids form ag...